Clinical Trials on Primary Bilary Cirrhosis (PBC) in United Kingdom

Total 315 results

CymaBay Therapeutics, Inc.

Terminated

Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis (PBC)

Germany, United States, Canada, United Kingdom, Poland
Mirum Pharmaceuticals, Inc.

Completed

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (CLARITY)

Primary Biliary Cirrhosis | PBC

United States, United Kingdom, Canada
Genfit

Completed

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cholangitis (PBC)

United States, United Kingdom, France, Germany, Spain
Ipsen

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

Primary Biliary Cholangitis (PBC)

United States, Spain, Korea, Republic of, Italy, France, Belgium, Australia, Czechia, Poland, Romania, New Zealand
Mirum Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis (VANTAGE)

Primary Biliary Cholangitis | PBC

United States, United Kingdom, Israel, Germany, Italy, France
Guy's and St Thomas' NHS Foundation Trust
King's College Hospital NHS Trust

Unknown

Paternally Inherited Phenotypes in Cholestasis (PIP-C)

Primary Sclerosing Cholangitis | Cholestasis | Primary Biliary Cirrhosis

United Kingdom
Light Chain Bioscience - Novimmune SA

Terminated

Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody (PIANO)

Primary Biliary Cirrhosis

Italy, United Kingdom
Newcastle-upon-Tyne Hospitals NHS Trust
Newcastle University; National Institute for Health Research, United Kingdom; Department of Health, United Kingdom

Completed

B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis (RITPBC)

Fatigue | Primary Biliary Cirrhosis

United Kingdom
Fast Forward Pharmaceuticals

Unknown

Pilot Study of FFP104 Dose Escalation in PBC Subjects

Primary Biliary Cirrhosis

Netherlands, United Kingdom
University of Alberta
GlaxoSmithKline; Axcan Pharma

Completed

Study of Combivir for Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Canada, United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus

Cholestasis, Intrahepatic

United Kingdom
Perspectum

Completed

Repeatability and Reproducibility of Quantitative MRCP

Liver Diseases | Primary Sclerosing Cholangitis | Gallstones | Primary Biliary Cirrhosis

United Kingdom
University of Birmingham
University Hospital Birmingham NHS Foundation Trust; Intercept Pharmaceuticals

Terminated

EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED Study (EXCITED)

Primary Biliary Cholangitis

United Kingdom
Intercept Pharmaceuticals

Completed

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, France, Germany, Spain, United Kingdom, Canada, Austria
Mirum Pharmaceuticals, Inc.

Withdrawn

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis (CASCADE)

Primary Biliary Cirrhosis

United States, United Kingdom
CymaBay Therapeutics, Inc.

Completed

Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Germany, United Kingdom, Canada
CymaBay Therapeutics, Inc.

Recruiting

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Hepatic Impairment | Compensated Cirrhosis | Primary Biliary Cholangitis

Korea, Republic of, United States, Spain, United Kingdom
Calliditas Therapeutics AB

Completed

Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.

Primary Biliary Cirrhosis

United States, Israel, Belgium, Germany, United Kingdom, Spain, Greece, Canada, Italy
The Cleveland Clinic

Completed

Pentoxifylline for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Christopher Bowlus, MD
Bristol-Myers Squibb

Completed

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

United States
University of California, Davis
Genentech, Inc.

Completed

Initial Study of Rituximab to Treat Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Intercept Pharmaceuticals

Completed

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

Primary Biliary Cirrhosis

United States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
George Brewer
FDA Office of Orphan Products Development

Completed

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
University of Florida
Shionogi Inc.; The PBCers Organization

Completed

Use of Fenofibrate for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
University of Miami
Mayo Clinic

Withdrawn

Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Ipsen

Active, not recruiting

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

Primary Biliary Cirrhosis

United States, France, Spain, Belgium, Germany, Switzerland, Brazil, United Kingdom, Argentina, Canada, Chile, Italy, South Africa, Turkey
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
Mayo Clinic
American College of Gastroenterology

Completed

Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC) (PBC)

Fatigue | Primary Biliary Cirrhosis

United States
Mayo Clinic

Active, not recruiting

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

United States
Mayo Clinic
UCB Pharma

Completed

Moexipril for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Zydus Therapeutics Inc.

Completed

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis (EPICS)

Primary Biliary Cirrhosis

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

Liver Cirrhosis, Biliary

United States, Puerto Rico
Target PharmaSolutions, Inc.

Active, not recruiting

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

Biliary Cirrhosis, Primary

United States
Janssen Research & Development, LLC

Completed

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cirrhosis

United States, Canada
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia
Intercept Pharmaceuticals

Completed

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
HighTide Biopharma Pty Ltd

Completed

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis (PRONTO-PBC)

Biliary Tract Diseases | Cholangitis | Cholestasis | Primary Biliary Cholangitis | Primary Biliary Cirrhosis | Bile Duct Stricture

United States
Mirum Pharmaceuticals, Inc.

Completed

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis (CAMEO)

Primary Sclerosing Cholangitis (PSC)

United States, United Kingdom, Canada
Albireo

Completed

An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects

Primary Biliary Cirrhosis | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis | Orphan Cholestatic Liver Diseases

United Kingdom
University of California, Davis

Completed

Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients

Primary Biliary Cirrhosis

United States
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia, New Zealand
Novartis Pharmaceuticals

Completed

A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients

Primary Biliary Cholangitis

United States, Germany, Russian Federation, Canada, United Kingdom, Poland
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more
University of Edinburgh
NHS Lothian

Completed

Prognostic Biomarkers For Acute Kidney Injury In Liver Cirrhosis

Biomarkers | Acute Kidney Injury | Liver Cirrhoses

United Kingdom
Intercept Pharmaceuticals

Terminated

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Liver Cirrhosis, Biliary

United States, Argentina, Spain, Belgium, Germany, Canada, Australia, Estonia, Brazil, Hungary, Italy, Lithuania
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Group

Completed

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES PBC)

Primary Biliary Cholangitis

United States
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Study Group

Withdrawn

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES-PBC)

Primary Biliary Cholangitis

United States
Yale University
American Liver Foundation

Suspended

Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States

Clinical Trials on Primary Bilary Cirrhosis (PBC) in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations